Travere Therapeutics (TVTX) Retained Earnings (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Retained Earnings came in at -$1.1 million in Q1 2026, down 100.07% YoY from $1.5 billion in Q1 2025, and up 99.93% on a QoQ basis from -$1.5 billion in Q4 2025.
Travere Therapeutics (TVTX) Retained Earnings (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Retained Earnings data on file, last reported at -$1.1 million in Q1 2026.
- Quarterly Retained Earnings fell 100.07% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 100.07% YoY) and the FY2025 annual result came in at -$1.5 billion, down 1840791.25% from the prior year.
- Retained Earnings climbed to -$1.1 million in Q1 2026, from -$1.5 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.5 billion in Q2 2025 to a low of -$1.5 billion in Q4 2025.
- A 5-year average of -$174764.7 and a median of -$1.1 million in 2026 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings soared 61572.33% — and 2025, when it sank 1840791.25%.
- Tracing TVTX's Retained Earnings over 5 years: stood at $1.1 billion in 2022, then sank by 206.19% to -$1.1 billion in 2023, then surged by 99.99% to -$80000.0 in 2024, then slumped by 1840791.25% to -$1.5 billion in 2025, then soared by 99.93% to -$1.1 million in 2026.
- The last three Retained Earnings figures came in at -$1.1 million (Q1 2026), -$1.5 billion (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.57 Bn |
| Mar 31, 2026 | -1.06 Mn |
| Dec 31, 2025 | -1.47 Bn |
| Sep 30, 2025 | -1.05 Mn |
| Jun 30, 2025 | 1.53 Bn |
| Mar 31, 2025 | 1.52 Bn |
| Dec 31, 2024 | -80,000.00 |
| Sep 30, 2024 | 1.36 Bn |
| Jun 30, 2024 | -1.33 Bn |
| Mar 31, 2024 | 1.34 Bn |
| Dec 31, 2023 | -1.13 Bn |
| Sep 30, 2023 | -3.65 Mn |
| Jun 30, 2023 | -1.19 Bn |
| Mar 31, 2023 | -2.18 Mn |
| Dec 31, 2022 | 1.06 Bn |
| Sep 30, 2022 | 303,000.00 |
| Jun 30, 2022 | -878.74 Mn |
| Mar 31, 2022 | -811.71 Mn |
| Dec 31, 2021 | -765.97 Mn |
| Sep 30, 2021 | -714.39 Mn |